Research programme: adenosine A3 selective antagonists - Domain Therapeutics

Drug Profile

Research programme: adenosine A3 selective antagonists - Domain Therapeutics

Alternative Names: DT 0522; DT 0738; FP 0522

Latest Information Update: 15 Jan 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Faust Pharmaceuticals
  • Developer Domain Therapeutics
  • Class 3-ring heterocyclic compounds; Pyrroles; Quinoxalines; Small molecules
  • Mechanism of Action Adenosine A3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Asthma; Cancer; Chronic obstructive pulmonary disease; Glaucoma

Most Recent Events

  • 26 Aug 2010 Pharmacodynamics data from a preclinical trial in Glaucoma presented at the 240th American Chemical Society National Meeting (2340th-ACS-2010)
  • 20 Nov 2009 Domain Therapeutics' selective adenosine A3 antagonists programme for glaucoma is available for partnering (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top